Tag - EPRX

Markets

Raymond James resumes coverage of Eupraxia at OP; PT $7 (Canadian)

Raymond James resumed coverage of Eupraxia Pharmaceuticals (TSX:EPRX) with an “outperform” rating and $7 (Canadian) price target. The stock closed at $1.36 on June 8. Eupraxia’s lead clinical candidate, EP-104IAR...

June 9, 2022

Markets

Raymond James starts Eupraxia Pharma at OP; PT $13 (Canadian)

Raymond James initiated coverage of Eupraxia Pharmaceuticals (TSX:EPRX) with an “outperform” rating and a $13 price target. The stock closed at $6.21 on April 12. Eupraxia aims to address the growing burden of...

April 13, 2021

Tag - EPRX

Raymond James resumes coverage of Eupraxia at OP; PT $7 (Canadian)

Raymond James starts Eupraxia Pharma at OP; PT $13 (Canadian)

General

More